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Abstract
Background: Gene expression microarray experiments are expensive to conduct and guidelines for acceptable quality
control at intermediate steps before and after the samples are hybridised to chips are vague. We conducted an
experiment hybridising RNA from human brain to 117 U133A Affymetrix GeneChips and used these data to explore the
relationship between 4 pre-chip variables and 22 post-chip outcomes and quality control measures.
Results: We found that the pre-chip variables were significantly correlated with each other but that this correlation was
strongest between measures of RNA quality and cRNA yield. Post-mortem interval was negatively correlated with these
variables. Four principal components, reflecting array outliers, array adjustment, hybridisation noise and RNA integrity,
explain about 75% of the total post-chip measure variability. Two significant canonical correlations existed between the
pre-chip and post-chip variables, derived from MAS 5.0, dChip and the Bioconductor packages affy and affyPLM. The
strongest (CANCOR 0.838, p < 0.0001) correlated RNA integrity and yield with post chip quality control (QC) measures
indexing 3'/5' RNA ratios, bias or scaling of the chip and scaling of the variability of the signal across the chip. Post-mortem
interval was relatively unimportant. We also found that the RNA integrity number (RIN) could be moderately well
predicted by post-chip measures B_ACTIN35, GAPDH35 and SF.
Conclusion: We have found that the post-chip variables having the strongest association with quantities measurable
before hybridisation are those reflecting RNA integrity. Other aspects of quality, such as noise measures (reflecting the
execution of the assay) or measures reflecting data quality (outlier status and array adjustment variables) are not well
predicted by the variables we were able to determine ahead of time. There could be other variables measurable pre-
hybridisation which may be better associated with expression data quality measures. Uncovering such connections could
create savings on costly microarray experiments by eliminating poor samples before hybridisation.
Published: 19 April 2006
BMC Bioinformatics 2006, 7:211 doi:10.1186/1471-2105-7-211
Received: 20 January 2006
Accepted: 19 April 2006
This article is available from: http://www.biomedcentral.com/1471-2105/7/211
© 2006 Jones et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
Page 2 of 18
(page number not for citation purposes)
Background
Conducting microarray experiments using Affymetrix
arrays is expensive. The quality of the starting material, for
instance human post-mortem tissues, is often predeter-
mined and samples may be scarce, leading to variable
quality of the extracted RNA. We set out to explore the
relationship between quality control (QC) variables used
to assess samples prior to hybridisation (pre-chip) and
those used to assess the quality of the hybridisation and
resulting microarray data (post-chip). We sought better to
define which variables were important in determining the
quality of the final data and to see in turn whether any
post-chip measures could predict pre-chip variables.
Examination of quality in GeneChip experiments has
been hampered by the relatively new technology, rapidly
changing platforms (chip types) and the inability of most
centres, because of expense, to run large series of samples
to examine the characteristics and limitations of the tech-
nology. In addition, the output of the QC measures
reflects both technical variation in the performance of the
experiment and the biological variation of the samples
available. Affymetrix give a series of guidelines about
threshold values for quality control measures produced in
the RPT file by their algorithm (GCOS or MAS 5.0) [1].
They do not really indicate what the user should do if the
quality control measures fall outside their recommenda-
tions except for omitting the sample from the analysis.
Dumur et al. [2] examined technical variables, the effect of
freezing cRNA and that of running the same samples on
different days and found that freezing had little effect but
hybridisation date did affect GeneChip QC variables.
They examined 18S/28S ratios in total RNA but found that
these did not appear to predict the efficiency of the cRNA
synthesis. Finkelstein [3] reported on improvements over
time in the quality of expression data obtained in the St
Jude's Children's Research Hospital from 2000–2004,
with over 5000 GeneChips hybridised. Finkelstein
attributes the improvements to technical advances in
hardware and software from Affymetrix and the increasing
experience of the centre: technical variations clearly had
the most impact on chip data in this longitudinal retro-
spective analysis. No attempt was made in this study to
examine the pre-chip variables that influence the Gene-
Chip performance. However, in studies examining the
effect of biological variability in the samples, the RNA
integrity of samples from human brain was found to
influence gene expression profiles profoundly; in turn
RNA quality was influenced by agonal state but not gen-
der, age or post-mortem interval (PMI: number of hours
from death until tissue preservation) [4,5].
We examined gene expression in a large series of RNA
samples extracted from post-mortem human brain [6]:
technical variation was minimised as far as possible. All
GeneChips came from two manufacturing batches, one
person carried out all the reactions and the same instru-
mentation was used for all hybridisations. There are only
limited variables that can be examined before GeneChips
are hybridised. We assessed total RNA quality subjectively,
using Agilent Bioanalyser traces, as well as with the Agi-
lent-derived RNA integrity number (RIN) [7]. We
excluded some samples based on their subjectively
assessed RNA quality as RIN became available only after
the samples had been hybridised (we later generated RIN
from the Agilent traces). We also examined the effect of
cRNA yield and PMI. We derived post-chip QC measures
from MAS 5.0 [8], dChip [9] and the Robust Multichip
Average (RMA) algorithms [10,11]. We used these meas-
ures as a quality control filter, initially in a subjective way,
to exclude samples that had been hybridised to Gene-
Chips from further analysis if they were regarded as out-
liers in the algorithms above [6].
We have now used these data to examine the relationship
of pre-chip variables to post-chip quality control meas-
ures. Although we believe our original subjective decision
to exclude samples at each step in the process from sample
collection to expression analysis was justified [5], these
decisions were based on limited understanding of the
relationship of the quality control measures to each other
and to the quality of expression data. By exploring the
relationship between the various pre- and post-chip qual-
ity control measures, we hope to move towards a more
objective assessment, combining key quality control
measures. This would reduce the chances of erroneous
sample exclusion or inclusion with its concomitant effect
in the reduction of power to detect altered mRNA levels
between the experimental conditions.
Results
Effect of brain region
The samples we used were derived from a series of HD and
control brains from the New Zealand Neurological Foun-
dation Human Brain Bank. The full consent of all families
was obtained at the time of autopsy and the University of
Auckland Human Subjects Ethics Committee approved
the protocols used in these studies. For most brains RNA
was isolated from three regions: caudate nucleus (CN),
cerebellum (CB) and motor cortex (MC). Because there
was a significant effect of brain region on some of the pre-
chip (RIN and cRNA yield) and post-chip variables (SF
and RawQ) (see methods for a detailed explanation of the
pre- and post-chip variables) we adjusted all variables for
brain region (see methods). All further analyses were car-
ried out with the adjusted variables.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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Table 1: Pre- and post-chip variables assessed in the current study on U133A arrays, with indications of the recommended acceptable 
range (where available) and summary statistics determined for samples in the current study. * None of the chips had significant spatial 
artifacts of hybridisation (e.g. scratches, uneven hybridisation) as assessed by visual inspection of the chip following hybridisation and 
by assessment of array and single outlier status across the chips. MAD is the median absolute deviation.
Variable Variable 
(abbreviated)
Recommended 
acceptable range
Summary statistics (current experiment)
Median MAD Range
Pre-chip variables
Post mortem interval 
hours
PMI empirical 12 3 4 29
Subjective RNA quality 4 
point scale
SUBQUAL empirical 3 1 1 4
RNA Integrity Number 
(RIN) 0 to 10
RIN empirical 7.8 0.9 4.3 9.5
Adjusted cRNA yield (µg) YIELD >15 µg5 7 7 3 0 8 3
Post-chip variables: assessed within MAS 5.0 (Affymetrix)
Background BG < 100 101.3 11.99 72.32 438.41
Noise (Raw Q) RAWQ 1.5 – 3.0 3.73 0.35 2.83 9.52
Noise NOISE empirical 5.76 0.82 3.85 38.2
%P PC_PRESENT 25 – 50% 47 2 24 53
Scaling Factor SF < 10 2.18 0.385 1.08 7.68
3'/5' ratio of β-Actin B_ACTIN35 < 3 1.6 0.26 0.98 55.87
3'/5' ratio of GAPDH GAPDH35 < 1.25 1.2 0.16 0.77 31.62
Post-chip variables: assessed within dChip [9]
PM/MM difference array 
outlier algorithm*
DCHIP_AR_OU
TLIER
< 5% 0.37 0.2 0.04 47.59
PM/MM difference single 
outlier algorithm*
DCHIP_SING_O
UTLIER
< 5% 0.09 0.03 0.04 2.3
%P DCHIP_PCCALL 25 – 50% 58.4 1.6 36.2 63.4
Median intensity MEDINT empirical 358 43.5 231 1620
Post-chip variables: assessed within Affy, Bioconductor, developed by Collin, 2005 [13]
Median NUSE MED_NUSE < 1.05 1.01 0.01 0.98 1.26
IQR.LR1 IQR_LR1 empirical 0.23 0.03 0.15 1.04
B.LR1 B_LR1 empirical 0.005 0.02 -0.11 0.24
IQRplusAbsB.LR1 IQRplusAbsB_LR
1
empirical 0.24 0.04 0.15 1.13
CV.LR1 CV_LR1 empirical 6.41 3.9 0.01 35.91
IQR.LR2 IQR_LR2 empirical 0.18 0.03 0.11 0.98
B.LR2 B_LR2 empirical 0 0.01 -0.1 0.22
IQRplusAbsB.LR2 IQRplusAbsB_LR
2
empirical 0.2 0.035 0.12 1.02
CV.LR2 CV_LR2 empirical 3.97 3.225 0 33.8
Post-chip variables: assessed within Affy, Bioconductor [13]
RNA degradation plot 
(gradient)
RNADEG_SLOP
E
empirical 2.27 0.27 0.86 3.96
RNA degradation plot (P- 
value from the linear 
regression)
PVAL_SLOPE empirical 2.67E-08 2.60e-8 4.21e-12 0.0049BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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Pre-chip variables
The pre-chip variables included two assessments of RNA
quality: a four-category subjective visual assessment of
Bioanalyzer traces (SUBQUAL) carried out by two of us on
all samples (AH, RL-C) and the Agilent-derived RIN,
which only became available after the GeneChips had
been hybridised and thus was generated retrospectively
(Figure 1). Subjective quality assessment was based on
ribosomal peak definition and apparent presence of low
molecular weight RNA (see methods). Figure 1 shows that
samples HC79CB, H131MC and H126CN, graded as
excellent (SUBQUAL = 4), have well resolved ribosomal
RNA peaks and virtually undetectable low molecular
weight RNA. HC117CB was graded good (SUBQUAL = 3)
and shows well-resolved rRNA bands but has a faint trace
of low molecular weight RNA. HC69CB was graded mod-
erate (SUBQUAL = 2); it has a less distinct 28S rRNA band
than seen at higher grades with visible low molecular
weight RNA. The remaining four samples were assessed as
poor quality RNA (SUBQUAL = 1). Here the 28S rRNA
band is blurred or invisible and there is substantial evi-
dence for the presence of low molecular weight RNAs. We
also investigated the effects of PMI and cRNA yield in the
final step of target preparation. Acceptable ranges and
details of the values obtained for our samples are given in
Table 1 and illustrated in Additional File 1.
As expected from post-mortem brain tissue, where there is
little control over the events leading up to availability and
preservation of tissue, PMI and RNA integrity as measured
by subjective and objective assessment were variable
(Table 1). In the original study a small number of samples
(N = 9) were excluded on the basis of subjective total RNA
quality, determined as above, and were therefore not
hybridised to arrays. Although they were samples at the
low end of the RNA quality spectrum, this decision was
somewhat arbitrary and driven by array availability rather
than their clear outlier status. A few samples of approxi-
mately equal subjective quality to those not hybridised to
arrays performed well on all post-chip quality control
assessments (Figure 1, sample HC83 CN). Although sam-
ple reactions were normalised with a reaction input of 10
µg, subsequent cDNA and cRNA reactions resulted in var-
iable yields of cRNA. A few samples (N = 4) were excluded
because they did not meet the minimum cRNA yield of 15
µg recommended by Affymetrix. Three of these samples
were originally rated subjectively as having poor quality
RNA.
PMI correlated moderately negatively with our subjective
assessment of RNA quality (treated as a numerical varia-
ble), with the Agilent RIN and with cRNA yield (Table 2).
As expected, subjective RNA quality was highly correlated
with the Agilent RIN (correlation coefficient 0.71, p =
0.000001; ANOVA F for linear trend 110.0 on 1 and 108
df, p = 3.6 × 10-18). Subjective quality and RIN also corre-
lated significantly with yield. Figure 1 shows the subjec-
tive assessment of RNA quality for a representative
selection of RNA samples of the entire quality spectrum
along with the corresponding RIN. The four subjective cat-
egories had considerable overlapping values for RIN: the
best RNA category had a RIN range of 7–9.5 and the poor-
est RNA category had a range of 4.3–7.7, with the other
two categories between these two.
Post-chip variables
We computed quality measures using three different soft-
wares: MAS 5.0 [8], dChip [9] and the Bioconductor pack-
ages affy and affyPLM [10,12,13] (see methods and Table
1). For most of these measures the relationship between
the measure and quality of quantitative expression data is
unknown. There is guidance about acceptable limits for
some measures, but currently the decision to exclude data
from analysis is empirical and generally based on outlier
status within each experiment: that is, chips that do not
look like other chips in the analysis are excluded. In our
experiment ten chips (out of 117) were flagged as outliers
as they were found to be outliers on multiple post-chip
variables (Table 3 and see Additional File 2). This was a
subjective decision based on recommended acceptable
ranges for each QC measure in the algorithms and the
extent to which the value for a particular sample fell out-
side the interquartile range for that measure in the exper-
iment (see Table 1). For some of the measures, e.g. RawQ,
although most of our samples were outside the recom-
mended range, there was little variation across the experi-
ment. All ten of the chips flagged as outliers were outside
the acceptable range recommended for MED_NUSE and
those eventually excluded had MED_NUSE ≥ 1.08 (Table
3). Measures that identified the same samples as outliers
were: PC_PRESENT, DCHIP_SING_OUTLIER,
MED_NUSE, NOISE, BG and MEDINT suggesting that to
Table 2: Correlations between pre-chip variables. Matrix of correlations (over the main diagonal) and p-values for difference from 0 
(under the main diagonal) between pre-chip variables.
YIELD PMI RIN SUBQUAL
YIELD * -0.22 0.29 0.34
PM 0.018 * -0.19 -0.21
RIN 0.002 0.043 * 0.71
SUBQUAL 0.0003 0.025 0.000001 *BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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Total RNA Gel images from the Bioanalyser (Agilent) Figure 1
Total RNA Gel images from the Bioanalyser (Agilent). Representative total RNA samples of varying quality, as 
assessed objectively by RIN and by subjective assessment. Selected corresponding pre- and post-chip variable assessments are 
also shown. Samples identified as outliers on post-chip quality control measures but not excluded are labelled (*); outliers 
excluded from expression analysis are labelled (**). Sample from case with prolonged agonal state (†). Sample not run on 
arrays due to poor quality total RNA (‡). n.d. is value not determined. CB, cerebellum; CN, caudate nucleus; MC, motor cor-
tex.
HC51 
CN
‡
HC71 
MC
**
HC83 
CN 
HC52 
MC
*
HC69 
CB 
H117 
CB 
HC79 
CB
**,†
H131 
MC
**
H126 
CN 
SUBQUAL 1 1 1 1 2 3 444
RIN 2.3 4.3 6.0 6.5 7.4 7.7 8.1 9.1 9.5
YIELD n.d. 36 45 56 62 74 44 48 61
BG n.d. 107 90 122 109 118 87 250 93
NOISE n.d. 4.7 4.8 6.0 6.4 7.1 5.5 38.2 5.5
PC_PRESENT n.d. 26 46 39 48 48 45 24 51
SF n.d. 7.7 2.9 3.6 2.0 1.8 1.7 1.1 1.9
B_ACTIN35 n.d. 4.0 2.0 3.9 1.9 1.6 55.9 1.6 1.4
GAPDH35 n.d. 4.1 1.3 2.1 1.2 0.96 31.6 1.1 1.0
DCHIP_AR_ 
OUTLIER 
n.d. 19.66 0.26 1.70 0.39 0.10 12.75 47.59 0.23
DCHIP_SING_ 
OUTLIER 
n.d. 1.23 0.10 0.20 0.14 0.04 0.38 2.30 0.10
MEDINT n.d. 266 296 331 378 424 327 1620 353
MED_NUSE n.d. 1.20 1.00 1.06 1.00 0.99 1.12 1.26 1.01
RNADEG_ 
SLOPE 
n.d. 2.67 2.90 3.61 2.53 2.19 3.96 1.17 2.20
PVAL_SLOPE n.d. 6.0 X 
10-10
1.5 X 
10-10
3.2 X 
10-11
2.0 X 
10-8
2.5 X 
10-8
1.0 X 
10-9
2.2 X 
10-5
2.9 X 
10-8
Figure 1 
0.2
0.5
1.0
2.0
4.0
6.0
kbBMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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Table 3: Pre- and post chip variables for samples flagged as potential outliers on at least one post-chip quality control measure. 
Samples were identified as outliers as judged empirically within the experiment and detailed in the results. Samples (*) were excluded 
from expression analysis. Samples from cases with prolonged agonal state (†). CB, cerebellum; CN, caudate nucleus; MC, motor 
cortex.
Pre-chip variables
Sample PMI SUBQUAL RIN YIELD
H104 CB 14 3 7.4 77
H122 CB*† 92 8 . 1 6 8
H85 CB*† 10 3 7.4 65
HC79 CB*† 44 8 . 1 4 4
H123 CN* 7.5 3 7.6 66
HC61 CN 6 3 7.1 59
H131 MC* 13 4 9.1 48
HC71 MC* 5 1 4.3 36
HC52 MC 23 1 6.5 56
HC55 MC 20 1 6.6 44
Post-chip variables: assessed within MAS 5.0 (Affymetrix)
BG RAWQ NOISE PC_PRESENT SF B_ACTIN35 GAPDH35
H104 CB 271 7.5 13.9 42 2.2 1.7 1.2
H122 CB*† 438 9.5 34.8 36 1.9 1.7 1.0
H85 CB*† 92 3.6 5.7 49 2.1 1.8 1.1
HC79 CB*† 87 3.4 5.5 45 1.7 55.9 31.6
H123 CN* 103 3.7 7.6 30 4.1 2.4 0.8
HC61 CN 119 4.0 5.2 43 4.0 1.5 1.2
H131 MC* 250 8.4 38.2 24 1.1 1.6 1.1
HC71 MC* 107 3.6 4.7 26 7.7 4.0 4.1
HC52 MC 122 4.2 6.0 39 3.6 3.9 2.1
HC55 MC 98 3.4 4.7 41 3.4 2.6 2.0
Post-chip variables: assessed within dChip (Li and Wong, 2001)
DCHIP_AR_OUTLIER DCHIP_SING_OUTLIER DCHIP_PCCALL MEDINT
H104 CB 2.71 0.61 55 597
H122 CB*† 14.72 1.85 41 1199
H85 CB*† 6.92 0.40 61 358
HC79 CB*† 12.75 0.38 55 327
H123 CN* 30.48 1.72 42 369
HC61 CN 4.05 0.58 57 287
H131 MC* 47.59 2.30 36 1620
HC71 MC* 19.66 1.23 39 266
HC52 MC 1.70 0.20 52 331
HC55 MC 3.19 0.29 53 294
Post-chip variables: assessed within Bioconductor packages affy, affyPLM and specialised code [15, 22]
MED_NUSE IQR_LR1 B_LR1 IQRplusAbs
B_LR1
CV_LR1 IQR_LR2 B_LR2 IQRplusAbs
B_LR2
CV_LR2
H104 CB 1.06 0.27 -0.048 0.32 17.3 0.27 -0.029 0.30 10.7
H122 CB*† 1.24 0.66 -0.105 0.76 16.0 0.64 -0.098 0.74 15.2
H85 CB*† 1.08 0.42 0.008 0.43 1.9 0.38 0.014 0.40 3.7
HC79 CB*† 1.12 0.56 -0.001 0.56 0.2 0.56 0.000 0.56 0.1
H123 CN* 1.26 0.67 0.241 0.91 35.9 0.65 0.220 0.87 33.8
HC61 CN 1.06 0.30 0.025 0.33 8.4 0.25 0.000 0.25 0.0
H131 MC* 1.26 1.04 -0.050 1.09 4.8 0.98 -0.040 1.02 4.1BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
Page 7 of 18
(page number not for citation purposes)
some degree they may be assessing similar characteristics.
Six of the identified outlier samples judged to have a com-
bination of the most extreme values were subsequently
excluded from analysis. The other four samples flagged as
outliers were not excluded from analysis because they had
less severe DCHIP_AR_OUTLIER and MED_NUSE values
and were not outliers on more than three other measures
(Table 3 and see Additional File 2).
The different algorithms generating the post-chip varia-
bles measure aspects of the same underlying hybridiza-
tion process. To explore the relationships between the
variables generated by the different algorithms we carried
out a principal component analysis using data from
U133A chips hybridised in the experiment for which
measures of all variables were available (N = 112). Since
many of the pre- and post-chip variables were not nor-
mally distributed, we based the principal component
analysis on Spearman (non-parametric) correlations. The
first 4 components explained 75% of the variation (Table
4 and Figure 2) with the remaining components each
assessing < 6%. The principal component analysis (Table
5) demonstrates that the different QC algorithms assess a
series of very similar parameters from the chips. The RMA-
QC and dChip algorithms assess the variation between
chips by comparing all chips: these measures form the first
principal component and account for around 1/3 of the
total variance. In contrast, MAS 5.0 computes single chip
measures. The MAS 5.0 scaling factor (SF) and the RMA-
QC median log ratio measure of bias (B_LR) contribute to
the second component: these measures reflect (in differ-
ent ways) how much adjustment of the total signal is
required to make one array comparable with the rest. The
second component also indexes the negative correlation
between high bias and low percentage present calls. The
percentage present call in both MAS 5.0 and dChip appear
to behave similarly, with high scaling factor or bias values
going together with low percentage present calls. MAS 5.0
and dChip assess 'noise' (third component), seemingly in
a very similar way, accounting for around 13% of the var-
iance. MAS 5.0 quantifies RNA integrity using 3'/5' ratios
of two index genes (B_ACTIN35, GAPDH35); the Biocon-
ductor affy package attempts this more globally by exam-
ining the 3'/5' ratio along the probes for all probesets
(RNADEG-SL, PVAL_SLOPE): this fourth component
accounts for 12% of the variance in post-chip measures.
These four principal components account for 75% of the
total variance and thus index the measures that are most
important among those considered in examining the
array expression summaries.
HC71 MC* 1.2 0.96 0.165 1.13 17.2 0.87 0.150 1.02 17.3
HC52 MC 1.06 0.43 0.063 0.49 14.5 0.34 0.039 0.38 11.3
HC55 MC 1.07 0.42 0.039 0.46 9.4 0.34 0.015 0.35 4.4
Post-chip variables: assessed within affy, Bioconductor
RNADEG_SLOPE PVAL_SLOPE
H104 CB 2.40 3.8 × 10-9
H122 CB*† 0.86 4.9 × 10-3
H85 CB*† 2.22 1.2 × 10-7
HC79 CB*† 3.96 1.0 × 10-9
H123 CN* 1.61 3.2 × 10-7
HC61 CN 2.40 9.7 × 10-9
H131 MC* 1.17 2.2 × 10-5
HC71 MC* 2.67 6.0 × 10-10
HC52 MC 3.61 4.2 × 10-12
HC55 MC 3.20 3.2 × 10-11
Table 3: Pre- and post chip variables for samples flagged as potential outliers on at least one post-chip quality control measure. 
Samples were identified as outliers as judged empirically within the experiment and detailed in the results. Samples (*) were excluded 
from expression analysis. Samples from cases with prolonged agonal state (†). CB, cerebellum; CN, caudate nucleus; MC, motor 
cortex. (Continued)
Table 4: Four main principal components explain ~75% of the variance in post-GeneChip QC measures)
Component % variance explained Cumulative variance explained
13 1 . 6 3 1 . 6
21 7 . 8 4 9 . 4
31 3 . 4 6 2 . 8
41 2 . 1 7 4 . 9BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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The first principal component (PC1) is highly correlated
with variables which include IQR of relative log expres-
sion (IQR_LR 1 and 2, and IQRplusAbsB_LR 1 and 2).
This quantity measures the variability in the degree to
which a given chip differs from a virtual median chip –
that is, a chip which would have median expression for
each probe set. Consistent with the property of principal
components of capturing the variability in the data, those
chips with highest IQR relative log expression tend to be
those which are largest on PC1 (Figure 3).
The largest outliers in Figure 3 are H131MC, HC71MC,
H123CN, H122CB, HC79CB, HC52MC, HC55MC and
H85CB. Examination of quality measures for these sam-
ples (Table 3) indicates that the chips are outliers for a few
different reasons rather than for the same underlying
Pairwise scatterplots for the first four principal components. Outlier chips (Table 3) are represented by blue triangles Figure 2
Pairwise scatterplots for the first four principal components. Outlier chips (Table 3) are represented by blue triangles.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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cause. Some of them would appear to have undergone
some degradation, particularly those with low SUBQUAL
and RIN (e.g. H122CB, HC52MC, HC55MC), while oth-
ers probably failed at some point of the hybridisation (e.g.
H131MC, H123CN).
Relationship of pre-chip to post-chip variables
Canonical correlation analysis was then performed in
order to detect relationships between the two sets of vari-
ables: the set of 4 pre-chip and that of 22 post-chip varia-
bles. Four canonical correlations were calculated (Table
6). These were used to investigate whether any of the pre-
chip variables were associated with the post-chip variables
in a way that would allow decisions to be made about
whether samples are of suitable quality to hybridise to an
array and give meaningful results.
The first canonical correlation (0.84, p < 0.001) indexes
nearly all of the relevant relationships between the pre-
and post-chip variables: it is highly significant (Table 6).
The second canonical correlation (0.59, p = 0.012) is also
significant but indexes much less of the relationship
between pre and post-chip variables. Post-mortem inter-
val makes very little contribution to either the first or sec-
ond canonical correlations (Table 7). RIN (or subjective
quality) and yield are, however, both important (Table 7).
Of the RMA QC measures, the MED_NUSE and B_LR,
IQR_LR and IQRplusAbsB_LR are all negatively correlated
with yield and RIN (Table 8). In MAS 5.0, SF and the 3'/5'
ratios are negatively correlated with yield and RIN, and %
present is positively correlated. So the lower the yield or
RIN, the higher the SF, median NUSE or bias and the 3'/5'
ratios: that is, the more 'correction' needs to be applied to
bring the errant chip in line with the others. Percentage
present call is positively correlated with yield and RIN in
both MAS 5.0 and dChip; this is likely to reflect the ability
to detect signal when both amount and quality of sample
are high. Most of the other post-chip variables are less
Table 5: Rotated component matrix for post-chip variables (U133A arrays, all samples)
QC measure Component
1234
IQR_LR1 0.934
IQR_LR2 0.928
IQRplAbsB_LR1 0.936
IQRplAbsB_LR2 0.938
DCHIP_AR_OUTLIER 0.771
MED_NUSE 0.769
DCHIP_SING_OUTLIER 0.557
CV_LR1 0.418
CV_LR2 0.327
B_LR1 0.905
B_LR2 0.855
SF 0.734
DCHIP_PCCALL -0.848
PC_PRESENT -0.866
NOISE 0.959
RAWQ 0.934
BG 0.928
MEDINT 0.874
B_ACTIN35 0.960
GAPDH35 0.946
PVAL_SLOPE 0.789
RNADEG_SL 0.427
Values less than 0.4 are not shown unless they are the largest for the corresponding variable
Table 6: Canonical correlation analysis to explore the relationships between two sets: a set of 4 pre-chip and a set of 22 post-chip 
variables
Canonical Correlation Approximate Standard Error Significance
1 0.838 0.028 < 0.0001
2 0.593 0.061 0.012
3 0.500 0.072 0.154
4 0.454 0.075 0.263BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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highly correlated in the first canonical correlation (Table
8). In the second canonical correlation the relationships
are considerably weaker and less significant. There is vir-
tually no effect of RIN, though SUBQUAL is negatively
correlated and YIELD positively correlated with measures
of 3'/5' ratios and noise.
Prediction of RIN using post-chip measures
Although estimation of RIN based on post-hybridization
measures is generally not of interest for a lab analyzing its
own data, it is potentially useful in the context of second-
ary analyses done by other labs. An increasingly common
example is analysis by different groups of publicly availa-
ble data, for example data deposited in Gene Expression
Omnibus (GEO) [14,15]. In this case there may not be
ready access to any pre-chip measures such as RIN. How-
ever, if the cel files are available, in the case of data derived
from Affymetrix chips for example, then post-hybridiza-
tion quality measures are readily computable. If the post-
chip measures that best predict RIN can be identified, then
confidence in excluding chips from secondary analyses on
the basis of poor quality RNA could be made and thus
improve the quality of data produced in any analysis.
However, RIN alone was not able to predict outliers in the
current study where samples had a range of RNA quality,
and we could not determine an accurate threshold of RIN
below which samples fail post-chip quality control.
In our data, excluding the gross outlier HC79CB, the sin-
gle variables most highly correlated with RIN are
B_ACTIN35, GAPDH35 and SF. B_ACTIN35 and
GAPDH35 are very highly correlated with each other (ρ =
0.99), with somewhat lower correlation with SF (ρ = .55 –
.65). Robust regression [16,17] of RIN on B_ACTIN35
yields the predictor
estimated RIN = 9.8 - 1.1 * B_ACTIN35,
with a residual standard error of about 0.9. Ordinary
regression yields nearly identical coefficients, both of
which are highly significant (p < 6 × 10-15), and an
adjusted R2 of 0.42. Using GAPDH35 as the predictor
yields
estimated RIN = 9.7 - 1.5 * GAPDH35,
with residual standard error of about 1.1. Again, coeffi-
cients estimated by ordinary regression are very close,
with highly significant coefficients (p < 2 × 10-12) and
adjusted R2 of 0.36. Including SF as an additional term
does not greatly improve the fit of the model. Using SF
alone, we obtain
estimated RIN = 9.4 - 0.7 * SF,
with residual standard error of about 1.0, highly signifi-
cant coefficients (p < 2.5 × 10-9) and adjusted R2 = 0.27. SF
may be easier to obtain than B_ACTIN35 or GAPDH35
for users without MAS/GCOS. Figure 4 shows the scatter
plots with regression lines for each of these scenarios. The
outlier chips (from Table 3 and Additional File 2) are indi-
cated in the plot (with the exception of HC79B, which is
a gross outlier on these measures). We thus see that RIN is
at least moderately predictable from measures readily
obtained from the MAS/GCOS rpt file and which are com-
putable from the cel file.
The effect of including chips that fail post-chip QC on 
analysis of differential gene expression
Figure 5 illustrates the effect of including a chip that did
not pass post-chip QC in the analysis on the detection of
differential gene expression between males and females in
cortex using different sample sizes (3, 4 or 5 per group).
Here, either one chip that failed post-chip QC is included
(the 'bad' group) or an age-matched 'good' chip is used so
that we can assess the effect of quality on numbers of
probesets detected as differentially expressed. Not surpris-
ingly, the effect is most marked when only small numbers
of replicates are available. The number of differentially
expressed genes at the selected p-values is less than half
the number detected when all the chips passed post-chip
QC. As larger sample sizes provide greater power, the
increased numbers of probesets detected as differentially
Pairwise scatterplots of PC1 vs IQR_LR1. Outlier chips  (Table 3) are represented by blue triangles Figure 3
Pairwise scatterplots of PC1 vs IQR_LR1. Outlier chips 
(Table 3) are represented by blue triangles.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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expressed should be mostly due to a reduced number of
false negative results.
Discussion
It would be very useful to be able to predict which samples
will go on to give interpretable results after hybridisation,
based on their pre-chip quality control variables. In some
cases, for instance when using post-mortem human tis-
sue, over which the researcher often has little control
before preparing the RNA, these considerations become
paramount. We examined the results we had obtained
using 117 brain RNA samples hybridised to U133A Gene-
Chips to see if we could establish any relationships
between pre- and post-chip variables. As it might also be
useful for the interpretation of data from the publicly
available resources we also examined whether we could
predict the RIN from the post-chip measures.
The two measures of RNA integrity we used were highly
correlated; these in turn correlated with cRNA yield indi-
cating that more intact total RNA will lead to better yields
at the end of the sample preparation process. Indeed, the
few samples that did not reach the Affymetrix recom-
mended 15µg cRNA yield were largely generated from
poor quality RNA. As we did not hybridise those samples
we judged to have RNA that was too degraded (by subjec-
tive assessment) or that did not generate sufficient cRNA
we cannot judge their impact on our post-chip measures.
Table 7: Canonical factor loadings of the pre-chip variables corresponding to the first and the second canonical correlations
Pre-chip QC Canonical variables
Pre-chip1 Pre-chip2
YIELD -0.526 0.363
PMI 0.140 0.112
RIN -0.934 0.099
SUBQUAL -0.847 -0.521
Table 8: Canonical factor loadings of the post-chip variables corresponding to the first and the second canonical correlations
Post-chip QC Canonical variables
Post-chip1 Post-chip2
RNADEG_SL 0.845
B_ACTIN35 0.532 0.280
GAPDH35 0.513 0.280
SF 0.497
B_LR1 0.364
B_LR2 0.345
IQR_LR1 0.289
IQR_LR2 0.366
IQRplAbsB_LR1 0.288
IQRplAbsB_LR2 0.343
MED_NUSE 0.337
DCHIP_AR_OUTL 0.337
DCHIP_SING_OUT 0.313
DCHIP_PCCALL -0.381
MEDINT -0.377
PC_PRESENT -0.339
CV_LR1
CV_LR2 0.376
BG 0.336
NOISE -0.284 0.275
RAWQ -0.287 0.303
PVAL_SLOPE 0.538
Values less than 0.25 are not shownBMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
Page 12 of 18
(page number not for citation purposes)
There are no reports assessing the performance of the Agi-
lent-generated RIN on GeneChip data quality to date.
Using the post-chip quality control measures in our exper-
iment, we found that samples with a RIN > 5.5 produced
expression data of sufficient quality to be included in
analyses. We found that longer post-mortem intervals
were associated with poorer quality RNA (lower RIN or
SUBQUAL) as might be expected, although the level of
correlation is low, around -0.2. Tomita et al. [5] found
that RNA integrity measures correlated well with their
measure of post-chip performance but that PMI was not
correlated with RNA integrity measures. In common with
previous reports, they did find that agonal factors (e.g. ter-
minal coma, pyrexia and coma) correlated better with
RNA integrity than with PMI [4,18]. Of the three samples
in our study derived from cases with prolonged agonal
state, none were clear outliers with respect to RNA quality
or cRNA yield compared with the rest of the RNA samples
in this experiment. They are likely to be too few and the
quality too variable in our experiment to separate them
out at this point but all three were clearly outliers on post-
chip measures. RNA integrity is also related to tissue pH
[4,18-20] and pH has been used as a surrogate measure of
RNA integrity as a result of pre- and post-agonal events.
We did not measure this in our samples, but given the rel-
ative ease of doing this test, it would be a worthwhile
measure in the absence of clinical information. The varia-
tion in RNA quality observed in our samples may in part
be due to PMI and agonal state, but these factors seem to
play only a small part in the variation of quality observed.
Other factors such as technical problems (e.g. freezing and
storage) and unknown physiological processes likely had
a greater impact.
The post-chip measures can be generated from data avail-
able in the public databases, but the pre-chip quality con-
trol measures are usually not provided. Therefore it might
prove useful to predict the RIN, as an objective measure of
RNA integrity, retrospectively. It is not clear how general-
isable the models generated from our data will be
although they indicate that there may be relationships
that can provide an estimate of this information. Only
examination of a large number of varied data sets will give
a true indication of their general validity. However, one of
these predictors might be used to obtain a 'quick and
dirty' estimate of the quality of RNA from which the data
is derived. More importantly, it highlights the most
appropriate post-chip measures that predict RNA quality
(B_ACTIN35 and GAPDH35 and to a lesser extent SF) and
gives an estimate of their relationship which can be used
to select chips to exclude from analysis based on their out-
lier status in these variables which would improve data
quality, particularly in small datasets or datasets com-
bined from several experiments.
Yield of cRNA is significantly correlated with measures of
RNA integrity. It is thus difficult to know if yield per se is
related to PMI or whether this is simply a result of its rela-
tionship with RNA integrity. Although yield clearly
reflects RNA integrity it also indexes the quality of the
reactions from total RNA to cRNA applied to the chips.
However, it is clear that yield and RNA integrity have dif-
ferent relationships with the post-chip QC factors. In our
experiment where all reactions were carried out by the
same person in large batches it is unlikely that there were
large variations in yield due to technical factors. Our study
is limited by having no systematic technical replicates, for
as in most such studies this would have been too expen-
sive. The only RNA sample that was re-hybridised to an A
chip, having been re-generated from RNA, was rated as
poor and failed on both occasions.
It is useful to distinguish between the various facets of the
catch-all term 'quality'. In chronological order: there is
first the condition of the starting RNA; next is the calibre
of the experimental process and resulting hybridisation;
finally comes the acceptability of the resulting expression
measures, including identification of outliers.
We can think of the first four principal components as
providing a grouping of post-chip measures, with each
component representing a different aspect of quality (see
Table 5): the first component reflects variables gauging
Pairwise scatterplots showing RIN plotted against (A)  B_ACTIN, (B) GAPDH and (C) SF. Outlier chips (Table 3)  are represented by blue triangles Figure 4
Pairwise scatterplots showing RIN plotted against (A) 
B_ACTIN, (B) GAPDH and (C) SF. Outlier chips (Table 3) 
are represented by blue triangles.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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array outliers, the second comprises variables assessing
array adjustment, the third contains variables measuring
hybridisation noise, and the fourth consists of the set of var-
iables related to RNA integrity. Interestingly, these compo-
nents correspond roughly to the three aspects mentioned
above, but in the reverse order. The first and second com-
ponents together give insight into the outlier status of a
chip when it is considered as part of a set of chips. The
component explaining most variability contains variables
providing numerical assessments for outlier identifica-
tion. A related but somewhat distinct aspect is given by an
assessment of how far off the chip is from the others, or
how the signal would need to be adjusted to make it more
like the rest of the chips in the set; this is provided by var-
iables strongly represented in the second component. The
third and fourth components, respectively, reflect directly
the second (hybridisation) and first (RNA integrity) areas
of quality.
It is notable that none of the quality assessment proce-
dures have measures in all four categories covered by the
principal components. The different algorithms appear to
mostly view quality from different, though overlapping,
perspectives. The measures provided by MAS 5.0 are most
prominent in the noise and integrity aspects, but also
touch on array adjustment. The RMA-QC measures dom-
inate in outlier identification, but also include array
adjustment; integrity is tangentially included in the affy
package [21] through the slope and corresponding p-
value. DChip measures also focus on outlier identification
and array adjustment, but include a noise variable as well
[9].
These different softwares are often used in conjunction
with one another, as indeed we did in our original analy-
sis. Presumably it is hoped that this increases the chance
of picking out all of the important variation, although it
may also increase the chances of excluding from the anal-
ysis chips with data of sufficient quality.
The relationships revealed by the canonical correlations
confirm that RNA perceived by subjective assessment or
RIN to be of high quality correlates strongly with post-
chip measures of 3'/5' integrity in the first canonical cor-
relation. This is reflected in the ability of B_ACTIN35 and
GAPDH35 to predict RIN retrospectively. RMA and dChip
measures do not explicitly index the 3'/5' ratios, seen in
the relationship between RIN and the affy package
RNADEG_SL, that the canonical correlations reveal to be
highly correlated: we did not use the RNADEG_SL in our
original decisions about which chips to exclude from
analysis. In retrospect it only identified 1 out of the 6 sam-
ples that we subsequently decided to drop from the anal-
ysis in our original method of exclusion and in fact
identified two other chips that we decided on balance to
include.
However, the scaling factor and median log ratios of RMA
expression are also strongly related to RNA integrity vari-
ables, indicating that scaling factors or bias should be as
consistent as possible across all chips in an experiment.
The relationship of SF to RIN is evidenced by its ability to
predict RIN without invoking the measures of 3'/5' ratios.
This is entirely logical as higher RNA integrity is related to
higher yield of cRNA and to a signal better able to be dis-
tinguished from the noise or background. Thus scaling
factors will be smaller and percentage present calls higher
if the RNA is of good quality, as shown by the first canon-
ical correlation. The less adjustment that needs to be
applied between different chips, the more likely that a
clearly interpretable signal will be obtained from an
experiment. That is, there will be increased sensitivity to
detect changes. Including data from a poor quality chip
affects the numbers of probesets considered to be differ-
The effect of including poor quality chips in analyses on ability  to detect differential gene expression Figure 5
The effect of including poor quality chips in analyses 
on ability to detect differential gene expression. 
Fewer differentially expressed genes are detected when 
comparing male and female motor cortex if a chip that failed 
QC is included in the analysis, reflected in the at least 50% 
fewer probe sets detected as differentially expressed at the 
two different p-value thresholds (t-test nominal unadjusted 
p-values). Bad (B) indicates comparisons where one chip that 
failed QC (HC71: female) was included in the analysis; Good 
(G) indicates comparisons where all chips passed QC. Sam-
ples were matched for age. This effect is most marked with 
very small chip numbers and gradually becomes less as chip 
numbers increase.BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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entially expressed very markedly; this effect is amplified
with smaller numbers of biological replicates. An FDR
adjustment [22] can control the false discovery levels in
the presence of poor quality chip data, but chips of poor
quality appear to substantially increase the number of
genes called as false negatives, as does reducing the num-
bers of biological replicates [23]. This is a result of
increased variance reducing the power to detect differen-
tial expression [24,25]. Archer et al. [26] suggest that one
way of rescuing some data from these poor quality chips
is to consider only those probesets for which all probes
fall within a defined distance of the 3' end of the gene,
although this fails to take into account the complexity of
RNA degradation, which is influenced by mRNA higher
order structure as well as length [27,28].
All the other variables in the first canonical correlation
have correlations of < 0.4 but users should note that lower
RNA integrity and yield predict lower %P calls, lower
median intensity and higher measures of signal variation.
The second canonical correlation shows much weaker
relationships and a big difference between RIN and SUB-
QUAL relationships to the post-chip variables. Good
yields combined with poor subjective quality appear to
predict higher background measures as though the entire
signal, including the noise, has been amplified.
Conclusion
Our results indicate that, as expected, close attention
should be paid to the RNA integrity of the original sam-
ple, as indexed subjectively or using RIN. In addition, if
cRNA yields are not consistent, despite consistent RNA
quality, then it may well be worth regenerating the sample
from total RNA before running it on a chip in order to
improve the yield. Yield which does not subsequently
improve may indicate that the sample should be aban-
doned as it will not produce sound results. PMI itself
appears not to be important in determining the quality of
final GeneChip data, but it is weakly related to RNA qual-
ity and may index some of this variation. Thus it may only
be necessary to exclude samples before hybridisation if
their RNA quality is insufficient. As determining RNA
quality is the first step in running such an experiment this
is clearly useful to know. Of the post-chip measures,
RNADEG_SL appears to index RNA integrity better than
the 3'/5' measures but both reflect the integrity of the orig-
inal RNA sample that is known prior to the hybridisation
step. Post-chip measures of the RNA integrity aspect of
quality are most useful for indicating when there has been
poor control of the RNA quality subsequent to its initial
integrity assessment, or for reinterpreting publicly availa-
ble data to enable prediction of its likely quality. In prac-
tice, for this experiment, expression data from chips that
passed our initial post-chip QC measures were derived
from samples with a RIN > 5.5.
It would be useful to identify a relationship between RNA
quality, cRNA yield and the subsequent quality of expres-
sion data in order to make informed decisions about RNA
samples to include in a microarray expression study.
However, in this study we have found that the post-chip
variables having the strongest association with quantities
measurable before hybridisation are those reflecting RNA
integrity. Other aspects of quality, such as noise measures
(reflecting the execution of the assay) or measures reflect-
ing data quality (outlier status and array adjustment vari-
ables) are not well predicted by the variables we were able
to determine ahead of time. To the extent that random
variation affects chip hybridisation, this finding is not
very surprising. However, we do not rule out the possibil-
ity that there are other variables measurable pre-hybridi-
sation which may be better associated with expression
data quality measures. Uncovering such connections
could create savings on costly microarray experiments by
eliminating poor samples before hybridisation. We there-
fore encourage investigators to keep careful track of poten-
tially relevant variables so that further studies may
continue to shed light on features predictive of array qual-
ity.
Methods
Expression dataset
A large set of post mortem brain samples (N = 134) that
had previously been included in an analysis of gene
expression using Human Genome U133A arrays (Affyme-
trix) were included in the current study (Table 9) [6].
These samples, representing three different brain regions
from male and female cases (N = 44) aged 34 to 94, were
prepared and processed according to standard protocols
(GeneChip® Expression Analysis Protocol, Rev. 2, March
2003, Affymetrix). Briefly, total RNA was extracted using
TRIzol (Invitrogen) followed by RNeasy column cleanup
(Qiagen) using the manufacturers' protocols. 10 µg total
RNA from each sample was used to prepare biotinylated
fragmented cRNA, with products from Affymetrix. Arrays
were hybridized for 16 h in a 45°C incubator with con-
stant rotation at 60 rpm. Chips were washed and stained
on the Fluidics Station 400, and scanned using the Gene-
Array® 2500, according to the GeneChip® Expression Anal-
ysis Protocol, Rev. 2, March 2003 (Affymetrix). All RNA
extractions and reactions were prepared using master
mixes and batches of 8 and 24 respectively. Arrays were
processed in batches of 16. All reactions and array hybrid-
isations were carried out by the same person. The U133A
GeneChips came from two manufacturing batches.
Gene expression was quantified by robust multi-array
analysis (RMA) [11] using the affy package [12], available
as part of the Bioconductor project [10]. Quality measures
were obtained from MAS 5.0 rpt files [8], dChip software
[9], Bioconductor package affyPLM [21] and specialisedBMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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routines for obtaining QC measures from robust regres-
sion [29]. The data are available as part of GEO accession
GSE3790.
Description of the variables assessed
A number of pre- and post-array variables were selected
for analysis on the basis of their predicted contribution to
quality control assessment at various points in the proce-
dure, from sample processing to expression data (Table 1
and below).
Pre-chip variables
Post mortem interval
(PMI) Post mortem interval was the time from death to
tissue preservation, in hours.
Subjective RNA quality
(SUBQUAL) 300 ng of total RNA was run on a 2100 Bio-
analyzer (Agilent Technologies). A pre-defined four cate-
gory subjective rating of RNA quality for all samples was
made independently by an experienced biologist (AKH)
and checked by another (RLC): in the few cases of disa-
greement (<5% of the total) the sample trace was re-eval-
uated and a consensus was reached. In performing this
assessment, attention to the following features of the total
RNA trace were made: ribosomal peak definition, baseline
flatness, and whether there were increased low molecular
weight species. Traces were used to classify RNA quality as
excellent, good, fair or poor. For subsequent statistical
analysis a value of 4 was assigned to samples considered
excellent, 3 to good, 2 to fair and 1 to poor total RNA
integrity. This rating was used to select samples for further
processing. Since a limited number of chips were available
for the experiment, a minority of samples rated as 1 were
not processed further, (although not all samples rated as
1 were excluded at this point) (Table 9 and Figure 1).
Objective RNA quality RIN
(RIN) Subsequent to the completion of the experiment,
2100 Bioanalyzer Expert software became available that
enabled automatic assessment of RNA quality for mam-
malian eukaryotic total RNA (Agilent Technologies). The
RNA integrity number (RIN) assesses RNA integrity on a
scale from 0 (low integrity RNA) to 10 (high integrity
RNA). The algorithm for generating a RIN number for a
given RNA sample is based on the entire electrophoretic
trace of the RNA sample. It uses an artificial neural net-
work based on the determination of the most informative
features that can be extracted from the traces out of 100
features identified through signal analysis. The selected
features which collectively capture the most information
about the integrity levels include the total RNA ratio (ratio
of area of ribosomal bands to total area of the electrophe-
rogram), the height of the 18S peak, the fast area ratio
(ratio of a defined area in the low molecular weight range
to the total area of the electropherogram) and the height
of the lower marker [7]. RINs were generated for all sam-
ples retrospectively with 210 Bioanalyzer software
(release B.02.02.SI238) using 2100 Bioanalyzer traces
made at the time of the experiment. The algorithm within
the Agilent software has been trained to identify electro-
pherogram traces that have an unusual shape and will not
return a RIN value in such cases [7]. A RIN number for 2
samples could not be determined and these were there-
fore excluded from the current analysis.
cRNA yield
(YIELD) A standard amount of total RNA (10 µg) was
used to carry out cDNA and subsequent cRNA reactions
for each sample. The yield of adjusted cRNA (corrected for
total RNA input) was used as a pre-chip parameter and
reflects both RNA quality and the technical variation of
the sample preparation.
Post-chip variables
(Affymetrix) quality control measures [8]
Background
(BG) Background is a measure of the fluorescent signal on
the array due to non-specific binding and autofluores-
cence from the array surface and the scanning wavelength
(570 nm). A high background may indicate the presence
of impurities such as cell debris or salts. This non-specific
binding causes a low signal to noise ratio, resulting in
reduced sensitivity for the detection of low expressing
mRNA.
Noise (Raw Q)
(RAWQ) Raw Q assesses the pixel to pixel variation within
each probe cell. Electrical noise from the scanner and sam-
ple quality can both contribute to Raw Q.
Noise
(NOISE) Noise is calculated by dividing the array into 16
zones. The standard deviation of the lowest 2% of signal
is calculated for each zone and then the average value for
all zones is determined. Noise is used to calculate back-
ground adjusted signal values by taking a weighted aver-
age of the zone-specific noise levels.
Percentage present
(PC_PRESENT) The number of probesets called "present"
relative to the total number of probesets on the array as a
percentage. A probeset is determined to be present, mar-
ginal or absent by a statistical algorithm within the MAS
5.0 software.
Scaling Factor
(SF) When global scaling is performed, the overall inten-
sity for each array is determined and is compared to a Tar-
get Intensity value in order to calculate the appropriateBMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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scaling factor. The Scaling Factor (calculated by the global
method) should be comparable between arrays.
3'/5' ratios of housekeeping genes (β-Actin, GAPDH)
(B_ACTIN35, GAPDH35 respectively) Expression values
for probesets specific to the 5', middle, or 3' portion of the
ACTB  and  GAPDH  transcripts are calculated from the
chip. The 3' and 5' probesets' expression values are
divided to give a ratio of 3'/5' mRNA representation.
dChip software quality control measures [9,30]
PM/MM difference array outlier algorithm
(DCHIP_AR_OUTLIER) The algorithm identifies outliers
as a result of image contamination or saturated PM or MM
signals. It cross-references one array with all the other
arrays in an experiment using modelling of both perfect
match (PM) and mismatch (MM) probe information at
the probeset level. It flags an array as an outlier if > 5% of
the probesets on that array are outliers relative to all other
arrays in the experiment and recommends discarding
arrays with >15% outlier probesets from analyses.
Single outlier algorithm
(DCHIP_SING_OUTLIER) The algorithm also determines
single outliers, individual probes within a probeset. These
are most likely due to cross-hybridization to non-target or
alternatively spliced genes.
%P
(DCHIP_PCCALL) Probesets that the dChip algorithm
considers to be greater than zero, i.e. expressed, are deter-
mined as a percentage of the total number of probesets,
similar to the Affymetrix %P.
Median intensity
(MEDINT) The median intensity is determined across the
array.
Bioconductor affy and affyPLM package quality control measures 
[13]
From affyPLM [21]
Median NUSE
(MED_NUSE) Standard error (SE) estimates for each
probeset on the array are taken and adjusted so that the
median standard error across all arrays is equal to 1.
Arrays with elevated SE relative to other arrays are typi-
cally of lower quality. Boxplots of these values are used to
compare arrays.
Relative Log Expression (RLE)
Values are computed for each probeset by comparing the
expression value on each array against the median expres-
sion value for that probeset across all arrays. The assump-
tion is that most genes have constant expression across
arrays, and thus have RLE values close to zero. Deviations
from this are assessed using boxplots. A number of statis-
tics within this analysis can be assessed as variables
including: inter-quartile range of log ratios (IQR_LR),
median (or bias) log ratio (B_LR), interquartile range plus
absolute median of log ratios (IQRplusAbsB_LR) andthe
coefficient of variation of log ratios (CV_LR) whichsum-
marise distributions of log ratios, or relative log expres-
sion, at the chip level. The relative log expression for each
probe set is obtained by subtracting a baseline log expres-
sion from the log expression of each probe set. Due to
computing limitations, we separated our experiment into
two sets of chips. We used one series to fit the RMA model,
and then applied the fitted model to all chips. Log ratios
are computed using two different sets of chips for base-
line. In LR1 the baseline is the probe set median log
expression for the fitting set of chips. In LR2, the baseline
is the median log expression from the group under study
itself.
RNA degradation plot (gradient)
(RNADEG_SLOPE) Within each probeset, probes are
numbered directionally from the 5' end to the 3' end.
Probe intensities are averaged by probe number, across all
probesets. Outlying arrays are identified as those with a
different gradient to the majority of plots within the
experiment. The P-value from the linear regression fit for
the RNA degradation plot is also assessed as a variable
(PVAL_SLOPE).
Table 9: The number of samples included at various steps in the process from total RNA to analysis of expression and in the current 
analysis of quality control measures
Sample numbers Cerebellum Caudate nucleus Motor Cortex Total
RNA 45 45 44 134
run on chips 39 41 37 117
included in array 
analysis [5]
36 41 35 112
included in QC 
correlations
36 38 35 117BMC Bioinformatics 2006, 7:211 http://www.biomedcentral.com/1471-2105/7/211
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Statistical analysis
All analyses were performed on the combined dataset for
all three brain regions (cerebellum, caudate nucleus, fron-
tal cortex) from a subset of samples (N = 112) for which
data was available for all variables (U133A arrays). Each
of the pre- and post- chip variables were adjusted by
"brain region" in order to remove the effect of the latter,
using the univariate general linear modelling technique
where the "brain region" variable was fitted as a fixed
effect. The residuals were considered as continuous varia-
bles and used for further analysis. The adjusted variables
were assessed for normality using Skewness and Kurtosis
measures in SPSS and distributions were considered non-
normal if they did not fall between 0–1.
Factor analysis was performed on 22 adjusted post-chip
variables (see above) using SAS PROC FACTOR. The anal-
ysis is based on the Spearman correlation matrix gener-
ated using the SAS PROC CORR. Initial factors were
extracted using the principal component method and
rotations were then performed by the VARIMAX method.
To assess relationships between the "pre-chip" and "post-
chip" multidimensional variables (4 and 22 dimensions
respectively), canonical correlation analysis was per-
formed using the SAS PROC CANCOR. As above, the
analysis was based on Spearman correlation matrix (SAS
PROC CORR).
For predicting RIN from post-chip variables, we assume a
linear model. High multicollinearity between variables
precludes formulation of a robust, interpretable model to
predict RIN based on post-chip variables. We thus consid-
ered simple models containing one or two predictors.
Robust linear regression modeling [16,17] of RIN based
on single variables highly correlated with RIN was used to
create simple prediction rules. We also used ordinary least
squares linear regression for comparison; results from
both methods were quite similar.
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